Antifungal mechanisms supporting boric acid therapy of Candida vaginitis

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 2, 2009, Pages 325-336

  De Seta, Francesco ^a,b   Schmidt, Martin ^c   Vu, Bao ^d   Essmann, Michael ^b   Larsen, Bryan ^b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b DES MOINES UNIVERSITY   (United States)

^c Des Moines University College of Osteopathic Medicine   (United States)

^d DRAKE UNIVERSITY   (United States)

Author keywords

Antifungal activity; Antifungal therapy; C. albicans; Vaginal infections

Indexed keywords

BORATE SODIUM; BORIC ACID; CEREBELLAR DEGENERATION-RELATED PROTEIN 1; ERGOSTEROL; FUNGAL PROTEIN; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL VIABILITY; BACTERIUM ISOLATE; BIOFILM; CANDIDA ALBICANS; CONCENTRATION RESPONSE; CONTROLLED STUDY; FUNGAL STRAIN; FUNGAL VIABILITY; FUNGUS GROWTH; FUNGUS HYPHAE; FUNGUS ISOLATION; GENE EXPRESSION; IN VITRO STUDY; INCUBATION TIME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PH; VAGINA CANDIDIASIS;

ANTIFUNGAL AGENTS; BACTERIA; BORIC ACIDS; CANDIDA ALBICANS; CANDIDIASIS, VULVOVAGINAL; COLONY COUNT, MICROBIAL; ERGOSTEROL; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY;

EID: 58849135784     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn486     Document Type: Article

References (27)

1. Centers for Disease Control and Prevention. Sexually Transmitted Disease Treatment Guidelines 2006.
2. McCormack W. Vulvovaginitis and cervicitis. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 6th edn. Philadelphia: Elsevier/Churchill Livingston, 2005; 1365-7.
3. Katz VL, Lentz GM, Lobo RA et al. Infections of the lower genital tract: Vaginitis. In: Comprehensive Gynecology. St Louis: Mosby Elsevier, 2007; 537.
4. Bieber EJ, Sanfilippo JS, Horowitz RA (eds). Vulvovaginal infections. In: Clinical Gynecology. Oxford: Churchill Livingston, 2007; 225.
5. Monif GRG, Baker DA (eds). Candida albicans. In: Infectious Diseases in Obstetrics and Gynecology, 6th edn. Boca Raton: Taylor and Francis, 2008; 310.
6. Ringdahl EN. Recurrent vulvovaginal candidiasis. Missouri Med 2006; 103: 165-8.
7. Swate TE, Reed JC. Boric acid for treatment of vulvovaginal candidiasis. Obstet Gynecol 1974; 43: 893-5.
8. Prutting SM, Cerveney JD. Boric acid vaginal suppositories: A brief review. Infect Dis Obstet Gynecol 1998; 6: 191-4.
9. Ray D, Goswami R, Banerjee U et al. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison to oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 2007; 30: 312-7.
10. Singh S, Sobel JD, Bhargava P et al. Vaginitis due to Candida krusei: Epidemiology, clinical aspects and therapy. Clin Infect Dis 2002; 35: 1066-70.
11. Van Slyke KK, Michel VP, Rein MF. Treatment of vulvovaginal candidiasis with boric acid powder. Am J Obstet Gynecol 1981; 141: 145-8.
12. Mossman RF. Chemical disposition of boron in animals and human. Environ Health Persp 1994; 102 Suppl 7: 113-7.
13. Di Renzo F, Cappelletti G, Broccia ML et al. Boric acid inhibits embryonic histone deacetylases: A suggested mechanism to explain boric acid-related teratogenicity. Toxicol Appl Pharmacol 2007; 220 178-85.
14. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast-Third Edition: Approved Standard M27-A3. Wayne, PA, USA: CLSI, 2008.
15. Burke D, Dawson D, Stearns T. Methods in Yeast Genetics. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 2000.
16. Larsen B, Anderson S, Brockman A et al. Key physiological differences in Candida albicans CDR1 induction by steroid hormones and antifungal drugs. Yeast 2006; 23: 795-802.
17. Arthington-Skaggs BA, Jradi H, Desai T et al. Quantitation of ergosterol content: Novel method for determination of fluconazole susceptibility of Candida albicans. J Clin Microbiol 1999; 37 3332-7.
18. Shin JH, Kee SJ, Shin MG et al. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: Comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 2002; 40: 1244-8.
19. Schmidt M, Barker S, Essmann M et al. Effect of commonly used herbicides on the virulence factor CDR1 in Candida albicans. Environ Toxicol Chem 2008; 27: 2346-51.
20. Windholz M (ed.) Merck Index, 10th edn. Rahway, NJ: Merck and Company Inc., 1983; 185.
21. Venkataraman N, Cole AL, Svoboda P et al. Cationic peptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 2005; 175: 7560-7.
22. Kale V, Trivendi R, Muley P. Proposed design of a dissolution apparatus for vaginal formulations containing probiotics. Dissolution Technol 2008; 15: 27-9.
23. Miers PD, Chow CK. Bacteriostatic and bactericidal actions of boric acid against bacteria and fungi commonly found in the urine. J Clin Pathol 1990; 43: 484-7.
24. Ralph SJ. Arsenic-based antineoplastic drugs and their mechanisms of action. Met Based Drugs 2008; 2008: Doi:10.1155/2008/260146.
25. Kitchen KT, Wallace K. The role of protein binding of trivalent arsenicals in arsenic carcinogenesis and toxicity. J Inorg Biochem 2008; 102: 532-9.
26. Jennings ML, Howren TR, Cui J et al. Transport and regulatory characteristics of the yeast bicarbonate transporter homolog Bor1p. Am J Physiol Cell Physiol 2007; 293: C468-76.
27. Kohno J, Kawahata T, Otake T et al. Boromycin, an anti-HIV antibiotic. Biosci Biotechnol Biochem 1996; 60: 1036-7.